Femasys’ (FEMY) Buy Rating Reaffirmed at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $12.00 price objective on the stock.

Separately, Chardan Capital reduced their target price on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Femasys Price Performance

FEMY opened at $1.58 on Wednesday. The firm has a market cap of $36.18 million, a PE ratio of -1.95 and a beta of -2.81. The stock has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.16. Femasys has a 1 year low of $0.86 and a 1 year high of $2.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FEMY. Aljian Capital Management LLC purchased a new stake in Femasys during the 3rd quarter valued at $27,000. XTX Topco Ltd grew its holdings in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the period. Geode Capital Management LLC increased its position in Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares during the last quarter. Virtu Financial LLC bought a new position in Femasys in the fourth quarter valued at about $25,000. Finally, Northern Trust Corp boosted its position in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.